Alimta and Gemcitabine in Non-Small Cell Lung Cancer
The aims of this study are: (1) to assess the safety and activity of gemcitabine plus Alimta (pemetrexed) regimen (GA regimen) in patients with advanced NSCLC patients in the context of a randomized trial, and (2) to compare the GA with the paclitaxel plus gemcitabine (PG regimen) in terms of toxicity and QoL
Non-Small Cell Lung Cancer|Stage IIIB or IV
DRUG: gemcitabine plus pemetrexed, paclitaxel plus gemcitabine
Response rate of patients treated with the gemcitabine plus Alimta regimen, after 3 cycles
Safety of patients treated with gemcitabine plus Alimta regimen, at the end of treatment|Quality of life of patients treated with gemcitabine plus Alimta regimen, after 3 cyces
Patients with stage IIIB or IV non-small cell lung cancer will be randomly allocated to receive: (a)PG regimen: paclitaxel 120 mg/sqm followed by gemcitabine 1,000 mg/sqm i.v. on days 1 \& 8 q 3 weeks; (b)GA regimen: gemcitabine 1,250 mg/sqm i.v. on day 1 (plus folinic acid 350 μg daily orally and vitamin B12 1,000 μg i.m. q 9 weeks), pemetrexed (Alimta®) 500 mg/sqm i.v. on day 8 followed by gemcitabine 1,250 mg/sqm, q 3 weeks.